Recent development in nano-sized dosage forms of plant alkaloid camptothecin-derived drugs

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 3, 2009, Pages 254-261

  Cuong, Nguyen Van ^a   Hsieh, Ming Fa ^a   Huang, Chun Ming ^b  

^a CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

9 nitrocamptothecin; Aminocamptothecin; Camptothecin; DNA topoisomerase I; Irinotecan; IT 101; Liposomal delivery; Nanomedicine; Nanoparticles; NK012; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 NC; BELOTECAN; CAMPTOTHECIN DERIVATIVE; CARBOXYLIC ACID; CPX 1; CYCLODEXTRIN; DILAUROYLPHOSPHATIDYLCHOLINE; DNA TOPOISOMERASE; IRINOTECAN; IT 101; LACTONE; LURTOTECAN; MACROGOL; MULTIDRUG RESISTANCE PROTEIN; NK 012; RUBITECAN; UNCLASSIFIED DRUG;

AEROSOL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DOSAGE FORM; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; HYPOKALEMIA; LIPOSOMAL DELIVERY; LUNG CARCINOMA; MULTIPLE CYCLE TREATMENT; NANOPHARMACEUTICS; NEUTROPENIA; PARTICLE SIZE; PHARYNGITIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TUMOR VOLUME;

ANIMALS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PATENTS AS TOPIC;

EID: 70350787374     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209789206913     Document Type: Review

References (64)

1. Verma RP, Hansch C. Camptothecins: A SAR/QSAR study. Chem Rev 2009; 109: 213-235.
2. Zhang L, Bao Y, Knang Y, Chen F. Synthetic studies on camptothecins part 1 An improved asymmetric total synthesis of (20S)-camptothecin. Helvetica Chim Acta 2008; 91: 2057-2061.
3. Niizuma S, Tsukazaki M, Suda H, et al. Synthesis of new camptothecin analogs with improved antitumor activities. Bioorg Med Chem Lett 2009; 19: 2018-2021.
4. Norbedo S, Dinon F, Bergamin M, et al. Synthesis of 6-amino-6-deoxyhyaluronan as an intermediate for conjugation with carboxylate-containing compounds: Application to hyaluronan-camptothecin conjugates. Carbohydr Res 2009; 344: 98-104.
5. Kusari S, Zuehlke S, Spiteller M. An endophytic fungus from camptotheca acuminata that produces camptothecin and analogues. J Nat Prod 2009; 72: 2-7.
6. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: Current perspectives. Bioorg Med Chem 2004; 12: 1585-1604.
7. Eliaz R, Nir S, Marty C, Szoka F. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 2004; 64: 711-718.
8. Griffiths G, Bailey S, Hambrook J, et al. Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine 1997; 15: 1933-1939.
9. Auguste D, Prud'homme R, Ahl P, Meers P, Kohn J. Association of hydrophobically-modified poly(ethylene glycol) with fusogenic liposomes. BBA-Biomembranes 2003; 1616: 184-195.
10. Xiong X, Huang Y, Lu W, et al. Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res 2005; 22: 933-939.
11. Han H, Lee A, Song C, et al. in vivo Distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm 2006; 313: 181-188.
12. Calvo P, Gouritin B, Chacun H, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001; 18: 1157-1166.
13. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006; 1: 297-315.
14. Hsieh MF, Lin TY, Gau RJ, et al. Biodegradable polymeric nanoparticles bearing stealth PEG shell and lipophilic polyester core. J Chin Inst Chem Eng 2005; 36: 609-615.
15. Koshkina N, Gilbert B, Waldrep J, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharm 1999; 44: 187-192.
16. Knight, J.V., Koshkina, N., Gilbert, B., Verschraegen C.F.: WO9915153 (1999).
17. 2-enriched air: Pharmacokinetic studies. Cancer Chemother Pharm 2001; 47: 451-456.
18. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharm 1999; 44: 187-192.
19. Waldrep, J.C., Knight, J.V., Koshkina, N.: US20026440393 (2002).
20. Perez-soler, R., Sugarman, S.M., Poirot, K.R.: US5834012 (1998).
21. Knight, J.V., Koshkina, N., Gilbert, B., Verschraegen, C.F.: US20087348025 (2008).
22. Knight, J.V., Koshkina, N., Gilbert, B., Verschraegen, C.F.: US20060204447 (2006).
23. Verschraegen, C.F., Knight, J.V., Koshkina, N., Gilbert, B.: US20080248096 (2008).
24. Chen J, Cai B, Ping Q, Liu M, Guo J. Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection. Drug Dev Ind Pharm 2008; 34: 853-859.
25. Chen J, Ping QN, Guo JX, Chu XZ, Song MM. Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm 2006; 32: 719-726.
26. Rahman, A., Ahmad, I.: US20050019387 (2005).
27. Yoshino, K., Nozawa, S., Isozaki, M., Sawada, S., Kato, I., Matsuzaki, T.: US20080069868 (2008).
28. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed NBM 2006; 2: 8-21.
29. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.
30. Cheng J, Khin KT, Jensen GS, Liu A, Davis ME. Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem 2003; 14: 1007-1017.
31. Cheng J, Khin KT, Davis ME. Antitumor activity of β-cyclodextrin polymer-camptothecin conjugates. Mol Pharm 2004; 1: 183-193.
32. Schluep T, Cheng J, Khin K, Davis M. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharm 2006; 57: 654-662.
33. Schluep T, Hwang J, Cheng J, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006; 12: 1606-1614.
34. Oliver JC, Yen Y, Synold TW, Schluep T, Davis M. A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors. J Clin Oncol 2008; 26 (Suppl; abstr 14538).
35. Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
36. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 2008; 60: 899-914.
37. Sumitomo M, Koizumi F, Asano T, et al. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res 2008; 68: 1631-1635.
38. Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci 2008; 99: 1258-1264.
39. Burris HA III, Infante JR, Spigel DR, et al. A phase I dose-escalation study of NK012. J Clin Oncol 2008; 26, No 15S (Suppl; abstr 2538).
40. Nakajima TE, Yanagihara K, Takigahira M, et al. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res 2008; 68: 9318-9322.
41. Liu Z, Robinson JT, Sun X, Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc 2008; 130: 10876-10877.
42. Dai, H., Liu Z., Lin X., Sun X.: WO2009018092 (2009).
43. Min, S.H., Choi, I.J.: US20036599519 (2003).
44. Sung, K.C., Chang, E.O., Song, I.S., Pai, C.M.: US20016322805 (2001).
45. Seo, Min.H., Choi, In.J.: US20036616941 (2003).
46. Kim, H.H., Yeo, G.D., Yi, Y.W.: US5548035 (1996).
47. Zhao, X.: US20046730334 (2004).
48. Leroux, J.C., Benahmed, A.S.: US20026338859 (2002).
49. Kang, H.W., Yim, E.Y.: WO2008038944 (2008).
50. Miura H, Onishi H, Sasatsu M, Machida Y. Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin. J Control Release 2004; 97: 101-113.
51. Onishi H, Machida Y, Machida Y. Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol Pharm Bull 2003; 26: 116-119.
52. Kunii R, Onishi H, Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm 2007; 67: 9-17.
53. Onishi H, Machida Y. Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy. Curr Drug Discov Technol 2005; 2: 169-183.
54. Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9-Nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics. Eur J Pharm Biopharm 2007; 66: 34-41.
55. Dadashzadeh S, Derakhshandeh K, Shirazi FH. 9-nitro-camptothecin polymeric nanoparticles: Cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Anti-Cancer Drugs 2008; 19: 805-811.
56. Gao J, Ming J, He B, Fan Y, Gu Z, Zhang X. Preparation and characterization of novel polymeric micelles for 9-nitro-20(S)-camptothecin delivery. Eur J Pharm Sci 2008; 34: 85-93.
57. Gao JM, Ming J, He B, Gu ZW, Zhang XD. Controlled release of 9-nitro-20(S)camptothecin from methoxy poly(ethylene glycol)-poly(D,L-lactide) micelles. Biomed Mater 2008; 3: 15013(doi: 10.1088/1748-6041/3/1/015013).
58. Lee W, Li Y, Chu I. Amphiphilic poly(D,L-lactic acid)/poly (ethylene glycol)/poly(D,L-lactic acid) nanogels for controlled release of hydrophobic drugs. Macromol Biosci 2006; 6: 846-854.
59. Chang Y, Chu I. Methoxy poly(ethylene glycol)-b-poly(valerolactone) diblock polymeric micelles for enhanced encapsulation and protection of camptothecin. Eur Polym J 2008; 44: 3922-3930.
60. William CZ, Suresh R, David MF, et al. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 2009; 15: 1466-1472.
61. Diederik FS, Kehrer AM, Bos JV, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: Urinary excretion predicts hematologic toxicity. J Clin Oncol 2002; 20: 1222-1231.
62. Graham GD, Calvert AH, Robert G, et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2005; 23: 1859-1866.
63. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-Nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10: 2319-2326.
64. Batist G, Gelmon KA, Chi KN, et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 692-700.